21 results on '"Poliero, Luca"'
Search Results
2. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania ‘Luigi Vanvitelli’
- Author
-
De Falco, Vincenzo, Poliero, Luca, Vitiello, Pietro Paolo, Ciardiello, Davide, Vitale, Pasquale, Zanaletti, Nicoletta, Giunta, Emilio Francesco, Terminiello, Marinella, Caputo, Vincenza, Carlino, Francesca, Di Liello, Raimondo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Orditura, Michele, De Vita, Ferdinando, Fasano, Morena, Napolitano, Stefania, Martini, Giulia, Della Corte, Carminia Maria, Franco, Renato, Altucci, Lucia, Ciardiello, Fortunato, and Troiani, Teresa
- Published
- 2020
- Full Text
- View/download PDF
3. Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
- Author
-
Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Della Corte, Carminia, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, and Martinelli, Erika
- Published
- 2021
- Full Text
- View/download PDF
4. How I treat anal squamous cell carcinoma
- Author
-
Martini, Giulia, Arrichiello, Gianluca, Borrelli, Carola, Poliero, Luca, and Martinelli, Erika
- Published
- 2019
- Full Text
- View/download PDF
5. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
- Author
-
Ciardiello, Davide, Blauensteiner, Bernadette, Matrone, Nunzia, Belli, Valentina, Mohr, Thomas, Vitiello, Pietro Paolo, Martini, Giulia, Poliero, Luca, Cardone, Claudia, Napolitano, Stefania, De Falco, Vincenzo, Giunta, Emilio Francesco, Ciaramella, Vincenza, Corte, Carminia della, Barra, Giusi, Selvaggi, Francesco, Franco, Renato, Marino, Federica Zito, Cuomo, Antonio, Morgillo, Floriana, Troiani, Teresa, Sibilia, Maria, Ciardiello, Fortunato, and Martinelli, Erika
- Published
- 2021
- Full Text
- View/download PDF
6. Overcoming immune-resistance in laryngeal cancer: a case report of the abscopal effect and nivolumab beyond progression
- Author
-
De Felice Marco, Arrichiello Gianluca, Tammaro Mariagrazia, and e Poliero Luca
- Subjects
Nivolumab ,Oncology ,Immunology ,Immunology and Allergy ,Humans ,Immunotherapy ,Lymph Nodes ,Radiosurgery ,Laryngeal Neoplasms - Abstract
The abscopal effect is defined as the systemic regression of distant neoplastic lesions induced by localized treatment. Although the first case reports date back to the beginning of the twentieth century, it remains a very rare event. In recent years, research and reporting on the subject has increased thanks to the development of new immune-checkpoint inhibitors (ICIs) and stereotactic body radiotherapy, as a consequence of molecular and clinical synergism. This work describes an extremely particular presentation of metastatic laryngeal cancer, with mediastinal abdominal nodes and bone progressive disease after PD-1 inhibitor failure, which resulted in reductions of bone pain and abdominal and thoracic lymphadenopathies and an improvement in clinical conditions after treatment with concurrent palliative radiotherapy on the bulky mediastinal node and ICI beyond progression, configuring an important abscopal response.Laryngeal carcinoma is the most common cancer site of the aerodigestive tract and accounts for 25–30% of all head and neck cancer cases. Multimodality treatment (chemotherapy plus surgery and radiotherapy) is pivotal in localized or locally advanced disease, while immunotherapy is reserved for relapsed and metastatic settings. Nivolumab resulted in median overall survival of 7.5 months, progression-free survival of 2.0 months and an estimated 1-year survival rate of 36%; however, the response rate is very poor, at about 14%. Integrating immunotherapy with radiotherapy may prolong the duration of response and enhance efficacy.
- Published
- 2022
7. sj-pptx-1-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
- Author
-
Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, and Napolitano, Stefania
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-pptx-1-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology
- Published
- 2022
- Full Text
- View/download PDF
8. sj-pptx-5-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
- Author
-
Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, and Napolitano, Stefania
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-pptx-5-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology
- Published
- 2022
- Full Text
- View/download PDF
9. sj-pptx-3-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
- Author
-
Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, and Napolitano, Stefania
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-pptx-3-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology
- Published
- 2022
- Full Text
- View/download PDF
10. sj-pptx-4-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
- Author
-
Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, and Napolitano, Stefania
- Subjects
110203 Respiratory Diseases ,FOS: Clinical medicine ,111702 Aged Health Care ,FOS: Health sciences ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified ,111299 Oncology and Carcinogenesis not elsewhere classified - Abstract
Supplemental material, sj-pptx-4-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology
- Published
- 2022
- Full Text
- View/download PDF
11. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
- Author
-
Caputo, Vincenza, primary, De Falco, Vincenzo, additional, Ventriglia, Anna, additional, Famiglietti, Vincenzo, additional, Martinelli, Erika, additional, Morgillo, Floriana, additional, Martini, Giulia, additional, Corte, Carminia Maria Della, additional, Ciardiello, Davide, additional, Poliero, Luca, additional, De Vita, Ferdinando, additional, Orditura, Michele, additional, Fasano, Morena, additional, Franco, Renato, additional, Caraglia, Michele, additional, Avitabile, Arianna, additional, Scalamogna, Roberto, additional, Marchi, Beatrice, additional, Ciardiello, Fortunato, additional, Troiani, Teresa, additional, and Napolitano, Stefania, additional
- Published
- 2022
- Full Text
- View/download PDF
12. Additional file 1 of Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
- Author
-
Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, Falco, Vincenzo De, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Carminia Della Corte, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, and Martinelli, Erika
- Abstract
Additional file 1: Supplementary table 1. Detailed values for combination index for each cell line and each niraparib + chemotherapeutics combination across 3 Effective Doses (EDs). ED50, ED75, and ED90 represent the required dose levels able to decrease cell viability to 50, 75, or 90%, respectively.
- Published
- 2021
- Full Text
- View/download PDF
13. Additional file 3 of Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
- Author
-
Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, Falco, Vincenzo De, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Carminia Della Corte, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, and Martinelli, Erika
- Abstract
Additional file 3: Supplementary table 3. BRCA2 mutations in the cell panel. Functional prediction according to FATHMM algorithm for COSMIC-identified non-synonymous, frameshift or truncating mutations of BRCA2 in our panel. Whenever available, Leiden Open Variant Database (LOVD) reference is also included [last accessed July 1st 2020].
- Published
- 2021
- Full Text
- View/download PDF
14. Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status
- Author
-
Vitiello, Pietro Paolo, primary, Ciardiello, Davide, additional, Cardone, Claudia, additional, Martini, Giulia, additional, Belli, Valentina, additional, Matrone, Nunzia, additional, Poliero, Luca, additional, Borrelli, Carola, additional, Vitale, Pasquale, additional, Zanaletti, Nicoletta, additional, Troiani, Teresa, additional, Melisi, Davide, additional, Ciardiello, Fortunato, additional, and Martinelli, Erika, additional
- Published
- 2019
- Full Text
- View/download PDF
15. Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways
- Author
-
Ciardiello, Davide, primary, Vitiello, Pietro Paolo, additional, Matrone, Nunzia, additional, Belli, Valentina, additional, Cardone, Claudia, additional, Poliero, Luca, additional, Borrelli, Carola, additional, Arrichiello, Gianluca, additional, Martini, Giulia, additional, Ciaramella, Vincenza, additional, Barra, Giusi, additional, Morgillo, Floriana, additional, Troiani, Teresa, additional, Melisi, Davide, additional, Ciardiello, Fortunato, additional, and Martinelli, Erika, additional
- Published
- 2019
- Full Text
- View/download PDF
16. Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
- Author
-
Vitiello, Pietro Paolo, De Falco, Vincenzo, Giunta, Emilio Francesco, Ciardiello, Davide, Cardone, Claudia, Vitale, Pasquale, Zanaletti, Nicoletta, Borrelli, Carola, Poliero, Luca, Terminiello, Marinella, Arrichiello, Gianluca, Caputo, Vincenza, Famiglietti, Vincenzo, Mattera Iacono, Valentina, Marrone, Francesca, Di Liello, Alessandra, Martini, Giulia, Napolitano, Stefania, Caraglia, Michele, and Lombardi, Angela
- Subjects
NUCLEIC acid analysis ,EPIDERMAL growth factor ,BODY fluid examination ,COLON tumors ,EXTRACELLULAR space ,LIVER tumors ,METASTASIS ,MOLECULAR biology ,GENETIC mutation ,NATURAL immunity ,RECTUM tumors ,RESEARCH evaluation ,TUMOR antigens ,GENETIC testing ,PREDICTIVE tests ,SEQUENCE analysis ,THERAPEUTICS - Abstract
Tumor heterogeneity represents a possible cause of error in detecting predictive genetic alterations on tumor tissue and can be overcome by testing alterations in circulating tumor DNA (ctDNA) using liquid biopsy. We assessed 72 consecutive patients with a diagnosis of metastatic colorectal cancer (mCRC) using Idylla™ Biocartis, a fully automated platform that evaluates the most frequent mutations of KRAS, NRAS and BRAF genes. We correlated the results of liquid biopsy and standard tissue-based next generation sequencing (NGS) analyses to patient clinical features. The overall agreement was 81.94%. Concordance was 85.71% and 96.15% in treatment-naïve patients and in the patient subgroup with liver metastases, respectively. In liver metastases positive, treatment-naïve patients, sensitivity, specificity and positive predictive value (PPV) were 92.31%, 100% and 100%, respectively. Circulating mutational fraction (CMF) was significantly higher in patients with liver metastases and high carcinoembryonic antigen (CEA) levels. In a subgroup of patients pre-treated with anti-Epidermal Growth Factor Receptor (EGFR) agents, emerging KRAS mutations were evidenced in 33% of cases. Testing RAS/BRAF mutations on plasma using the Idylla™ Biocartis platform is feasible and reliable in mCRC patients in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. How I treat anal squamous cell carcinoma
- Author
-
G. Arrichiello, L. Poliero, Giulia Martini, Erika Martinelli, C. Borrelli, Martini, Giulia, Arrichiello, Gianluca, Borrelli, Carola, Poliero, Luca, and Martinelli, Erika
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,HPV ,medicine.medical_treatment ,Disease ,Review ,chemo-radiotherapy ,lcsh:RC254-282 ,SCCA ,Anus Neoplasm ,Internal medicine ,Medicine ,Humans ,Stage (cooking) ,Papillomavirus Infection ,multidisciplinary team ,Salvage Therapy ,Chemotherapy ,business.industry ,Papillomavirus Infections ,Anal Squamous Cell Carcinoma ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Anus ,Anus Neoplasms ,Clinical trial ,Radiation therapy ,Clinical research ,medicine.anatomical_structure ,Carcinoma, Squamous Cell ,Neoplasm Recurrence, Local ,business ,Human - Abstract
Squamous cell carcinoma of the anus (SCCA) is a rising health issue, strongly related to other relevant medical conditions such as (HIV) and human papillomavirus (HPV) infection. Correct assessment of patients with SCCA requires a multidisciplinary evaluation and adequate follow-up. Accurate local and systemic staging, as well as risk evaluation, are essential to optimal treatment planning. Early stage tumours can be definitively treated with a combination of chemotherapy and radiotherapy, while salvage surgery is usually reserved for patients who develop local recurrence. Distant recurrence and de novo metastatic disease are associated with poorer prognosis and require palliative systemic chemotherapy, with different single agent and combination options available. Finally, recent discoveries on the carcinogenesis of SCCA have allowed the development of innovative treatment options, the most promising being immune checkpoint inhibitors. The limited systemic treatments for SCCA and low incidence of the disease, together with insufficient data from clinical research could explain the poor outcomes of these patients, which should therefore be managed in high volume centres and enrolled in clinical trials whenever possible. This article summarises the main strategies for treating patients with SCCA.
- Published
- 2020
18. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience
- Author
-
Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani, Stefania Napolitano, Caputo, Vincenza, De Falco, Vincenzo, Ventriglia, Anna, Famiglietti, Vincenzo, Martinelli, Erika, Morgillo, Floriana, Martini, Giulia, Corte, Carminia Maria Della, Ciardiello, Davide, Poliero, Luca, De Vita, Ferdinando, Orditura, Michele, Fasano, Morena, Franco, Renato, Caraglia, Michele, Avitabile, Arianna, Scalamogna, Roberto, Marchi, Beatrice, Ciardiello, Fortunato, Troiani, Teresa, and Napolitano, Stefania
- Subjects
liquid biopsy ,Oncology ,mCRC ,precision medicine ,clinical trial ,cfDNA - Abstract
Background: Recently, new evidence of the next-generation sequencing (NGS) liquid biopsy utility in clinical practice has been developed. This assay is emerging as a new promising tool to use as a noninvasive biomarker for cancer mutation profiling. Additional data supporting the clinical validity of cell free DNA (cfDNA) based testing is necessary to inform optimal use of these assays in the clinic. Materials and methods: A total of 398 cancer patients were analyzed by FoundationOne Liquid Analysis (F1LA), a genomic profiling assay and by standard NGS diagnostic ThermoFisher platform. The association between diagnostic technique was evaluated using a Poisson regression model. FoundationOne Liquid (F1L) and FoundationOne Liquid CDx (F1LCDx) detect 70 and 324 cancer-related genes alterations, respectively, including genomic signatures tumor fraction, blood tumor mutational burden (only for the 324 genes version), and microsatellite instability high status. Both assays used a single DNA extraction method to obtain cfDNA. The real-life clinical impact and feasibility of F1L and F1LCDx were evaluated across different solid tumors in our department. Results: Between 1 January 2019 and 28 February 2021, 398 samples of different tumor types from 398 patients were analyzed (overall success rate: 92%, in FoundationOne Liquid CDx Analysis success rate: 97%). Most frequent molecular alterations were TP53 (74), APC (40), DNMT3A (39), KRAS (23). The comprehensive clinical impact of F1LA compared with standard diagnostic was 64.7% versus 22.1% [risk ratio (RR) = 2.94; p Conclusions: Although additional studies are needed to better select patients and setting, NGS F1LA is a useful, noninvasive, and repeatable assay to guide therapeutic choice in oncology. It provides a snapshot of cancer heterogeneity profile that could be incorporated in routinely clinical practice.
- Published
- 2022
19. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening?
- Author
-
C. Borrelli, Fernando Paragliola, Stefania Napolitano, Carminia Maria Della Corte, G. Arrichiello, Erika Martinelli, Giulia Martini, Valeria Nacca, L. Poliero, Arrichiello, Gianluca, Poliero, Luca, Borrelli, Carola, Paragliola, Fernando, Nacca, Valeria, Napolitano, Stefania, Corte, Carminia Maria Della, Martini, Giulia, and Martinelli, Erika
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Immune checkpoint inhibitors ,medicine.medical_treatment ,Population ,Complex disease ,Internal medicine ,medicine ,Humans ,education ,RC254-282 ,education.field_of_study ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Microsatellite instability ,Immunotherapy ,medicine.disease ,digestive system diseases ,Clinical trial ,Female ,DNA mismatch repair ,Colorectal Neoplasms ,business - Abstract
Immunotherapy has recently become a major treatment modality for several types of solid tumours, achieving remarkable and long-lasting remissions. In metastatic colorectal cancer patients (mCRC), immune checkpoint inhibitors (ICIs) were found to be effective as treatment for deficient mismatch repair (dMMR)/ microsatellite instability high (MSI-H) tumours and received regulatory approval for this indication. However, mCRC is a complex disease and dMMR/MSI-H tumours represent a minority of the cases; therefore, new strategies are needed to extend the benefits of immunotherapy to a larger population of patients. This review explores the immunological differences between dMMR/MSI-H and proficient mismatch repair (pMMR)/ microsatellite instability low (MSI-L) tumours, focuses on new proposed biomarkers to predict response to immunotherapy and illustrates results reported from the main clinical trials with immunotherapeutic agents in CRC, addressing the most promising approaches being currently developed.
- Published
- 2021
20. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype
- Author
-
Claudia Cardone, Fortunato Ciardiello, Giusi Barra, Thomas Mohr, Maria Sibilia, Francesco Selvaggi, Vincenzo De Falco, Pietro Paolo Vitiello, Federica Zito Marino, Floriana Morgillo, Antonio Cuomo, Teresa Troiani, Renato Franco, Stefania Napolitano, Valentina Belli, Giulia Martini, Davide Ciardiello, Erika Martinelli, Carminia Maria Della Corte, B. Blauensteiner, Nunzia Matrone, L. Poliero, Vincenza Ciaramella, Emilio Francesco Giunta, Ciardiello, Davide, Blauensteiner, Bernadette, Matrone, Nunzia, Belli, Valentina, Mohr, Thoma, Vitiello, Pietro Paolo, Martini, Giulia, Poliero, Luca, Cardone, Claudia, Napolitano, Stefania, De Falco, Vincenzo, Giunta, Emilio Francesco, Ciaramella, Vincenza, Corte, Carminia Della, Barra, Giusi, Selvaggi, Francesco, Franco, Renato, Marino, Federica Zito, Cuomo, Antonio, Morgillo, Floriana, Troiani, Teresa, Sibilia, Maria, Ciardiello, Fortunato, and Martinelli, Erika
- Subjects
Male ,Cancer Research ,Colorectal cancer ,0302 clinical medicine ,Cell Movement ,Databases, Genetic ,Receptor ,0303 health sciences ,Hematology ,EMT ,General Medicine ,Middle Aged ,Prognosis ,3. Good health ,Gene Expression Regulation, Neoplastic ,Benzocycloheptenes ,Oncology ,030220 oncology & carcinogenesis ,Quinolines ,Biomarker (medicine) ,Female ,Signal transduction ,Colorectal Neoplasms ,Signal Transduction ,medicine.medical_specialty ,Epithelial-Mesenchymal Transition ,Adenocarcinoma ,TGFβ ,03 medical and health sciences ,Downregulation and upregulation ,Cell Line, Tumor ,Proto-Oncogene Proteins ,Spheroids, Cellular ,Internal medicine ,medicine ,Humans ,Galunisertib ,Protein Kinase Inhibitors ,Aged ,030304 developmental biology ,Original Paper ,business.industry ,Receptor, Transforming Growth Factor-beta Type II ,Computational Biology ,Receptor Protein-Tyrosine Kinases ,AXL ,Triazoles ,medicine.disease ,Axl Receptor Tyrosine Kinase ,Cell culture ,Cancer research ,Pyrazoles ,Neoplasm Recurrence, Local ,business - Abstract
A subset of colorectal cancer (CRC) with a mesenchymal phenotype (CMS4) displays an aggressive disease, with an increased risk of recurrence after surgery, reduced survival, and resistance to standard treatments. It has been shown that the AXL and TGFβ signaling pathways are involved in epithelial-to-mesenchymal transition, migration, metastatic spread, and unresponsiveness to targeted therapies. However, the prognostic role of the combination of these biomarkers and the anti-tumor effect of AXL and TGFβ inhibition in CRC still has to be assessed. To evaluate the role of AXL and TGFβ as negative biomarker in CRC, we conducted an in-depth in silico analysis of CRC samples derived from the Gene Expression Omnibus. We found that AXL and TGFβ receptors are upregulated in CMS4 tumors and are correlated with an increased risk of recurrence after surgery in stage II/III CRC and a reduced overall survival. Moreover, we showed that AXL receptor is differently expressed in human CRC cell lines. Dual treatment with the TGFβ galunisertib and the AXL inhibitor, bemcentinib, significantly reduced colony formation and migration capabilities of tumor cells and displayed a strong anti-tumor activity in 3D spheroid cultures derived from patients with advanced CRC. Our work shows that AXL and TGFβ receptors identify a subgroup of CRC with a mesenchymal phenotype and correlate with poor prognosis. Dual inhibition of AXL and TGFβ could represent a novel therapeutic strategy for patients with this aggressive disease. Supplementary Information The online version contains supplementary material available at 10.1007/s12032-021-01464-3.
- Full Text
- View/download PDF
21. How I treat anal squamous cell carcinoma.
- Author
-
Martini G, Arrichiello G, Borrelli C, Poliero L, and Martinelli E
- Subjects
- Humans, Neoplasm Recurrence, Local, Papillomavirus Infections, Salvage Therapy, Anus Neoplasms, Carcinoma, Squamous Cell
- Abstract
Squamous cell carcinoma of the anus (SCCA) is a rising health issue, strongly related to other relevant medical conditions such as (HIV) and human papillomavirus (HPV) infection. Correct assessment of patients with SCCA requires a multidisciplinary evaluation and adequate follow-up. Accurate local and systemic staging, as well as risk evaluation, are essential to optimal treatment planning. Early stage tumours can be definitively treated with a combination of chemotherapy and radiotherapy, while salvage surgery is usually reserved for patients who develop local recurrence. Distant recurrence and de novo metastatic disease are associated with poorer prognosis and require palliative systemic chemotherapy, with different single agent and combination options available. Finally, recent discoveries on the carcinogenesis of SCCA have allowed the development of innovative treatment options, the most promising being immune checkpoint inhibitors. The limited systemic treatments for SCCA and low incidence of the disease, together with insufficient data from clinical research could explain the poor outcomes of these patients, which should therefore be managed in high volume centres and enrolled in clinical trials whenever possible. This article summarises the main strategies for treating patients with SCCA., Competing Interests: Competing interests: EM: advisory board for Amgen, Bayer, Merck, Roche, Sanofi, Servier and expert opinion for European Society of Medical Oncology., (© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.